Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel shows promise for rosacea redness in small study

NCT ID NCT07431476

Symptom relief Sponsor: Istanbul Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a gel containing brimonidine to see if it can reduce persistent facial redness in people with rosacea. In the first part, 45 adults applied the gel to one side of their face and a placebo to the other, measuring redness after a few hours. In the second part, they used the gel on both sides daily for one month. Redness was measured with a skin color device, magnified images, and patient reports.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brimonidine gel
What this could lead to
If it works, this could offer a reliable topical option to reduce persistent facial redness in people with rosacea.
What could go wrong
This is a small, completed Phase 4 study with only 45 participants. Results may not apply to all rosacea types, and long-term safety beyond one month is not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

45 people

The number who actually took part.

Started

May 2025

Finished

Aug 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Clinical diagnosis of erythematotelangiectatic rosacea (ETR) according to the National Rosacea Society (NRS) diagnostic criteria * Presence of persistent facial erythema consistent with ETR * Symmetrical facial involvement adequate for split-face assessment * No more than two inflammatory facial lesions at screening * Ability and willingness to comply with all study procedures, including acute Day 1 assessments and the 1-month follow-up visit * Willingness to apply topical brimonidine gel daily during the 1-month period and to avoid initiating new rosacea treatments during the study * Provision of written informed consent Exclusion Criteria: * Individuals younger than 18 years. * Presence of three or more inflammatory facial lesions. * Prior use of BT (brimonidine tartrate) for facial erythema. * Use of topical or systemic treatments for rosacea or other dermatoses without completing the required washout period. * Presence of other facial dermatoses * Withdrawal of consent (the only discontinuation criterion)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rosacea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression rosacea telangiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rosacea Rosacea subtype 1 (erythematotelangiectatic)

Contacts and locations

Locations

  • Istanbul Training and Research Hospital, Department of Dermatology

    Istanbul, 34098, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.